Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Hansa Biopharma expands leadership team with dedicated roles for Corporate Communications, Investor Relations and Business Development

Company strengthens its dedicated communications team with the appointment of Rolf Gulliksen as Head of Corporate Communication and Klaus Sindahl as Head of Investor Relations. Emanuel Björne, previously VP Investor Relations and Business Development, will assume a new position as VP Global Business Development to fully focus on the partnership opportunities for Hansa’s proprietary enzymology platform.Lund, Sweden, April 29, 2019 – Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the Company

ÅF welcomes world leading Performance Venue Acoustician

ÅF Sound & Vibration appoints Dr. Thomas Scelo as Performing Arts Senior Acoustician. Thomas has extensive experience with performance venues from leading roles at Marshall Day Acoustics, most recently as partner and Managing Director for the greater Hong Kong region. Thomas will start his new role at ÅF Sound & Vibration on May 1st 2019. Thomas is a world leading performance venue acoustician with more than 40 prestigious projects in his portfolio.  Philharmonie de Paris, Melbourne's Hamer Hall and the Changsha Meixihu International Culture and Art Centre are just a few.

Interim report January - March 2019

NET ASSET VALUE AND THE LATOUR SHARE ·The net asset value rose to SEK 119 per share, compared with SEK 100 per share at the start of the year. This is an increase of 18.9 per cent. By comparison, the Stockholm Stock Exchange's Total Return Index (SIXRX) increased by 13.2 per cent. The net asset value was SEK 124 per share at 26 April. 1) ·The total return on the Latour share was 11.2 per cent during the year measured against the SIXRX, which rose 13.2 per cent. INDUSTRIAL OPERATIONS ·The industrial operations' order intake rose 22 per cent to SEK 3,332 m (2,723 m),

INVISIO: Invitation to Q1 2019 conference call on May 6 at 10.00 CEST

INVISIO is pleased to invite press, investors and analysts to a conference call on May 6 at 10.00 CEST where CEO Lars Højgård Hansen present the INVISIO 2019 first quarter results.The conference call, which will be held in English, will begin with a presentation of the interim results followed by a Q&A session.The interim report will be announced on May 2, 2019.Phone number for the conference:To participate in the conference call, use the dial-in numbers below. Please dial in 5-10 minutes prior to the scheduled start time in order to facilitate a timely start.Sweden: +46 (0)8 5069

OKEA prepares for its first drilling operation to target further upside potential within and surrounding the Draugen field

Trondheim, 29th of April 2019: OKEA has on behalf of PL093, secured the semi-submersible rig Deepsea Nordkapp to drill for upside opportunities within and surrounding the Draugen field. The drilling operation is expected to commence in Q4 2019. Deepsea Nordkapp will drill one infill pilot well in the Draugen field and one exploration well in the “Skumnisse” prospect, north-east of Draugen, both within the OKEA-operated PL093 license. Deepsea Nordkapp is a 6th generation dynamically positioned harsh environment and winterized semi-submersible drilling rig on a two-year lease

PowerCell and Bosch sign joint development and licensing agreement regarding PowerCell S3

PowerCell and Robert Bosch GmbH have signed an agreement regarding the development, production and sale of the PowerCell S3 fuel cell stack for the automotive segment. The agreement includes a joint development of the S3 and a license whereby Bosch gets the exclusive right to produce and sell the new and improved version of PowerCell S3 for automotive applications such as cars, trucks and buses. Bosch will pay PowerCell MEUR 50 (approx. MSEK 530) for the license and a royalty fee for every product sold.The MEUR 50 payment will have a positive impact on the operating income for the second

Financial Report January - March 2019

Financial Summary - Q1'19 · Consolidated Net Sales $494 million · Net Sales growth (17)%, Organic Sales1 growth (12)%  · Active Safety Net Sales growth (10)%, Organic Sales1 growth (3)%  2019 Outlook  · Light vehicle production decline low to mid single digits versus 2018 · Organic Sales1 decline in the mid single digits versus 2018 · Currency translation impact on sales unchanged at ~(2)% versus 2018 · Operating loss, cash flow weaker in H1'19, expected improvement in H2'19 Business Highlights · Veoneer Order Book at the beginning of 2019 was more than

XVIVO has received market approval (PMA) from the FDA for STEEN Solution™ and XPS™

On April 26, 2019 XVIVO received Premarket approval (PMA) from the FDA for the products XPS™ and STEEN Solution™ for sale on the American market. The approval means that STEEN Solution™, XPS™ and the accompanying single-use articles are the only medical device products that are approved for Ex Vivo Lung Perfusion (EVLP) of initially unacceptable donated lungs at body temperature. This press release is an updated version of the press release sent April 27, 2019 at 12:30 a.m.Please see FDA press release on the following link:https://www.fda.gov/news-events/press-announcements/fda-approves-

Summa Equity wins ESG Award at the Private Equity Awards 2019

Summa Equity won the Environmental, Social and Governance (ESG) Award at the Private Equity Awards 2019 for incorporating the Sustainable Development Goal (SDG) framework in shaping the long-term strategy of its portfolio companies, measuring the effect and innovating to address the global challenges.   “We are honored to win the Environmental, Social and Governance Award at the Private Equity Awards 2019, one of the oldest and most respected tributes in our industry,” says Reynir Indahl, Managing Partner of Summa Equity. “To outperform, one cannot be agnostic to the challenges we as a

Follicum files patent application for new topical formulation of FOL-005 for hair loss

Using easy-to-apply cream instead of direct scalp injection would extend patent protection by 8 years Follicum AB ("Follicum" or "the company") today announced that the company's hair  loss treatment projects are progressing according to plan and a patent application for an internally developed formulation of FOL-005 has been submitted.  The cream formulation is intended to be lubricated into the scalp and has demonstrated good hair-stimulating effect in an animal model. The next step involves running a clinical phase II study in alopecia patients which is expected to start at the end of

Invitation to presentation of BioArctic’s Interim Report for the first quarter of 2019 on May 9, at 9.30 a.m. CET

Stockholm, Sweden, April 29, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – March 2019 on Thursday,May 9, 2019 at 08:00 a.m. CET. BioArctic invites to an audiocast with teleconference (in English) for investors, analysts and media on May 9, at 09:30 – 10:30 a.m. CET. Gunilla Osswald, CEO, and Jan Mattsson, CFO, to present BioArctic and comment on the Interim Report for the first quarter of 2019 followed by a Q&A-session. Sweden: + 46 8 505 583 53Denmark: + 45 781 501 07Germany: + 49 692 222 203 80The

Lynparza receives positive EU CHMP opinion for 1st

29 April 2019 07:00 BST Lynparza receives positive EU CHMP opinion for 1st-linemaintenance treatment of BRCA-mutated advanced ovarian cancer AstraZeneca and MSD's Lynparza is the only PARP inhibitor to demonstratean improvement in progression-free survival for patients in this setting AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending Lynparza(olaparib) as a 1st-line

Nitro Games Oyj: Interim Report Jan – Mar 2019

Reporting period January – March 2019 · Revenues (Jan - Mar): 25,2 KEUR (571,0 KEUR on corresponding period 2018). · EBITDA: – 1 315,5 KEUR (- 953,6 KEUR). · EBIT: –1 472,1 KEUR (-1 110,3 KEUR). · Net profit: –1 474,9 KEUR (-1 114,7 KEUR). · Cash and cash equivalents: 2 029,8 KEUR (31 March 2019). · Short-term receivables: 168,6 KEUR (31 March 2019). Significant events during January – March 2019 · Started cooperation negotiations: streamlining organization and teams, executing cost savings. · New roadmap for Heroes of Warland: First updates were released

Wihlborgs letting an additional 1,700 m² for police training at Malmö University

Last summer, Malmö University signed an agreement with Wihlborgs for 9,000 m² for police training in Malmö. Now the university has signed a ten-year agreement for an additional 1,700 m², primarily lecture halls.Police training at Malmö University started in January, and in August the training is moving to Kranen 2 in Dockan. Wihlborgs is currently conducting a substantial redevelopment of this property to meet the need for space for research facilities, firearms ranges, training environments and a garage for police vehicles, among others. These premises will enter operation in July 2019 and

Hansa Biopharma Interim Report January–March 2019

MAA filing of IDEFIRIX (imlifidase) in Europe marks a milestone in Hansa’s evolution into a commercial stage biopharmaceutical companyJanuary – March 2019 Highlights · The European Medicines Agency (EMA) accepted Hansa’s Marketing Authorization Application (MAA) for review of IDEFIRIX (imlifidase). This acceptance marks the beginning of the regulatory review process for IDEFIRIX in the European Union (EU). IDEFIRIX has both EU Orphan Drug Designation and PRIority MEdicine (PRIME) designation. An opinion of the EMA Committee for Medicinal Products for Human Use (CHMP) is expected within

Nordic Nanovector appoints Fredrik Haavind as Head of Legal and Compliance

Oslo, Norway, 29 April 2019 Nordic Nanovector ASA (OSE: NANO) announces the appointment of Fredrik Haavind as the newly established Head of Legal and Compliance. Mr Haavind has 16 years of broad legal and compliance experience in Norwegian and International businesses, including international contracts law, governance and compliance, M&A, corporate and securities laws and regulations, with experience from in-house legal departments, law firms and the courts. He joins Nordic Nanovector from Fugro N.V., a global provider of geo-intelligence listed on Euronext, Amsterdam, where he acted as

Q1 2019: Revenue growth and strong cash flow starts the year

Significant events in the first quarter · First-quarter net sales rose to MSEK 138, up 16%, or MSEK 19 compared with the first quarter 2018 · EBITDA increased by MSEK 11, up 64% compared with the first quarter 2018 · Early repayment of a bank loan totalling MSEK 60 reflects the strength of Probi’s balance sheet and cash flow · Ongoing launches of Probi® Osteo, for the prevention of bone loss in postmenopausal women. Strong customer interest and several customer launches planned in 2019 Financial overview MSEK Q1 Q1 2018 Full-year 2018

Ovako publishes additional climate declarations to help customers make climate-smart purchasing decisions

Ovako, which has previously published climate declarations for its Hofors, Smedjebacken and Boxholm production flows, today publishes another climate declaration for its production facility in Imatra, as well as updated versions of previous declarations. The climate declarations enable comparison of Ovako’s carbon footprint per kilogram of finished steel product, from raw material until the finished product leaves the company’s production facilities, with the global average. The declarations, which show that Ovako’s products have an 80 percent lower carbon footprint than the global

Read original

SBB, Interim Report January – March 2019: Net income after tax for the period amounted to SEK 216m

SAMHÄLLSBYGGNADSBOLAGET I NORDEN AB (PUBL): Interim Report January – March 2019 in brief: · Rental income increased to SEK 429m (390). · The operating surplus increased to SEK 240m (233). · Cash flow from operating activities before changes of working capital was SEK 97m (40). · Profit before tax was SEK 349m (151), of which: · Income from property management is included with SEK 106m (73). The management result includes costs for early redemption of loans and other non-recurring financing costs of SEK -25m. · Unrealized changes in the value of properties

Medivir appoints new CFO

Stockholm, Sweden – Medivir AB (Nasdaq Stockholm: MVIR) today announces the appointment of Magnus Christensen as new CFO of Medivir effective as of 12 August 2019. He will also join the company’s management team. In his role, Magnus will be responsible for Investor Relations as well as leading the day-to-day operations within the areas of finance, IT, HR and premises. Magnus Christensen, whose most recent position was as CFO at O’Learys Trademark, has extensive experience of managerial positions within finance from a range of companies. “I’m delighted to welcome Magnus to Medivir,”

Tecnotree signs delivery agreement on Digital BSS Suite 5 worth USD 15 million

Tecnotree CorporationStock Exchange Release29 April 2019 at 9:00 a.m. (EEST)Tecnotree has signed an agreement with one of the largest telecom operators in the Middle East region. The value of the agreement is USD 15.8 million for 2 years. Under the agreement, Tecnotree will deploy its Digital BSS Suite 5 products to help accelerate the operator’s business growth as well as increase agility and operational efficiency of their IT systems. Tecnotree has a long-standing relationship with the customer. Earlier, Tecnotree helped them to transform to a world leading CRM & Product Catalog

Hemfosa acquires properties in Sweden, Norway and Finland

Hemfosa has made acquisitions in all three markets for a total underlying property value of approximately MSEK 575 and annual rental income of about MSEK 42. The acquisitions in Sweden and Norway complement the existing portfolio in locations where Hemfosa already owns properties and offer potential for development. Hemfosa is also entering the preschool segment in Finland with the acquisition of four preschools in Oulu.Acquisitions in Sweden  In Motala, Hemfosa acquired four properties totaling about 12,800 square meters. These properties are situated in central Motala and house schools,

Share buy-backs in Telia Company during week 17 2019

During the period April 23, 2019, until April 26, 2019, Telia Company AB (publ) (LEI code 213800FSR9RNDUOTXO25) has repurchased in total 2,488,171 own shares (ISIN: SE0000667925). The share buy-backs form part of the SEK 5 billion share buy-back programme that Telia Company announced on April 16, 2019. The share buy-back programme, which runs between April 16, 2019, and February 28, 2020, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulation").During the period

There are no items matching the current filter
There are no more items matching the current filter
Back to top